Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Azacitidine With Carboplatin and Paclitaxel for Newly Diagnosed Ovarian Cancer

This study has been terminated.
(No enrollment. Unable to recruit due to lack of eligible patients.)
Sponsor:
Collaborator:
Celgene Corporation
Information provided by:
Loyola University
ClinicalTrials.gov Identifier:
NCT00842582
First received: February 11, 2009
Last updated: March 8, 2011
Last verified: March 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: March 2012
  Estimated Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)